




MO HEALTHNET PHARMACY PROGRAM AND BUDGET UPDATE


MHD DRUG PA COMMITTEE SEPTEMBER 16, 2021 JOSH MOORE, PHARM D-DIRECTOR OF PHARMACY




Eligibles by Group July 2021 Total Eligibles 1,098,103











FY22 Pharmacy Spend vs Total Medicaid Spend Total Spend \$992,865,377.50 July 2021



Pharmacy Expenditures FY22 July 2021-Sept 2021




PHARMACY PROGRAM TOP 4 DRUG CLASSES PER FY


HICL Description	FY 2019
PALIPERIDONE PALMITATE (Invega)	\$40,792,733
LURASIDONE HCL (Latuda)	\$37,240,789
ADALIMUMAB (Humira)	\$30,733,203
ANTIHEMOPHILIC FACTOR(FVIII)RECOMBINANT	\$25,767,689
HICL Description	FY 2020
PALIPERIDONE PALMITATE (Invega)	\$47,932,570
LURASIDONE HCL (Latuda)	\$36,752,596
ADALIMUMAB (Humira)	\$35,512,453
METHLYPHENIDATE HCL (ADHD)	\$28,435,400
HICL Description	FY 2021
HICL Description PALIPERIDONE PALMITATE (Invega)	FY 2021 \$50,536,989
·	
PALIPERIDONE PALMITATE (Invega)	\$50,536,989
PALIPERIDONE PALMITATE (Invega) ADALIMUMAB (Humira) LURASIDONE HCL (Latuda)	\$50,536,989 \$47,544,776 \$40,495,985
PALIPERIDONE PALMITATE (Invega) ADALIMUMAB (Humira)	\$50,536,989 \$47,544,776
PALIPERIDOÑE PALMITATE (Invega) ADALIMUMAB (Humira) LURASIDONE HCL (Latuda) METHYLPHENIDATE HCL (ADHD)	\$50,536,989 \$47,544,776 \$40,495,985
PALIPERIDONE PALMITATE (Invega) ADALIMUMAB (Humira) LURASIDONE HCL (Latuda) METHYLPHENIDATE HCL (ADHD) HICL Description	\$50,536,989 \$47,544,776 \$40,495,985 \$30,831,744 FYTD 2022
PALIPERIDOÑE PALMITATE (Invega) ADALIMUMAB (Humira) LURASIDONE HCL (Latuda) METHYLPHENIDATE HCL (ADHD)	\$50,536,989 \$47,544,776 \$40,495,985 \$30,831,744 FYTD 2022 \$13,354,087
PALIPERIDONE PALMITATE (Invega) ADALIMUMAB (Humira) LURASIDONE HCL (Latuda) METHYLPHENIDATE HCL (ADHD) HICL Description PALIPERIDONE PALMITATE (Invega)	\$50,536,989 \$47,544,776 \$40,495,985 \$30,831,744 FYTD 2022

Pharmacy Expenditures/Eligibles Per FY


Table 23



HEP C FY 2018 -FYTD 2022



SYNAGIS EXPENDITURES FY2019-FYTD2022



FY2019-FYTD 2022 Rare Disease Expenditures

